Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.
| Revenue (Most Recent Fiscal Year) | $14.08M |
| Net Income (Most Recent Fiscal Year) | $-33.50M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 62.18 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 11.25 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -237.88% |
| Net Margin (Trailing 12 Months) | -237.88% |
| Return on Equity (Trailing 12 Months) | -42.39% |
| Return on Assets (Trailing 12 Months) | -32.48% |
| Current Ratio (Most Recent Fiscal Quarter) | 15.73 |
| Quick Ratio (Most Recent Fiscal Quarter) | 15.73 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.40 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.01 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.17 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.17 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 195.48M |
| Free Float | 155.80M |
| Market Capitalization | $875.74M |
| Average Volume (Last 20 Days) | 2.31M |
| Beta (Past 60 Months) | 0.74 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 43.79% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |